AD hallmarks are used by the National Institute on Aging and Alzheimer’s Association (NIA-AA) to categorize existing AD biomarkers under Aβ deposition, pathologic tau, and neurodegeneration [AT(N)] research framework, enabling a biological definition of AD [8]. This evidence concerns the gene MAPT and Alzheimer disease.